Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPIXNASDAQ:IOBTNYSE:JATTNASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPIXESSA Pharma$1.69+1.8%$1.65$1.40▼$7.88$75.02M1.69338,641 shs9,320 shsIOBTIO Biotech$1.21+0.8%$0.99$0.66▼$1.73$79.72M0.09273,734 shs154,436 shsJATTJATT Acquisition$1.04+1.0%$1.26$7.80▼$12.38$17.94MN/A41,322 shs689,639 shsMISTMilestone Pharmaceuticals$1.54+10.8%$1.19$0.63▼$2.75$82.34M0.86898,371 shs960,702 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPIXESSA Pharma+1.81%-1.17%-3.98%-1.74%-72.74%IOBTIO Biotech+0.83%+23.47%+28.72%+10.00%-9.02%JATTJATT Acquisition+0.97%-13.33%-30.20%-25.71%-81.09%MISTMilestone Pharmaceuticals+10.79%+26.23%+32.76%-24.51%-12.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPIXESSA Pharma1.9844 of 5 stars2.03.00.00.03.12.51.3IOBTIO Biotech2.895 of 5 stars3.74.00.00.02.10.81.3JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMISTMilestone Pharmaceuticals2.9536 of 5 stars3.25.00.00.03.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPIXESSA Pharma 2.00Hold$2.0018.34% UpsideIOBTIO Biotech 3.33Buy$9.33671.35% UpsideJATTJATT Acquisition 0.00N/AN/AN/AMISTMilestone Pharmaceuticals 2.40Hold$17.001,003.90% UpsideCurrent Analyst Ratings BreakdownLatest JATT, MIST, EPIX, and IOBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/1/2025MISTMilestone PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/1/2025MISTMilestone PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/28/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/17/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/12/2025IOBTIO BiotechPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/5/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/28/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPIXESSA PharmaN/AN/AN/AN/A$2.68 per shareN/AIOBTIO BiotechN/AN/AN/AN/A$2.02 per shareN/AJATTJATT AcquisitionN/AN/A$0.04 per share27.08($0.53) per shareN/AMISTMilestone Pharmaceuticals$1M82.33N/AN/A$0.50 per share3.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-24.61%-23.87%8/4/2025 (Estimated)IOBTIO Biotech-$86.08M-$1.37N/AN/AN/AN/A-86.56%-75.24%8/12/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AMISTMilestone Pharmaceuticals-$59.69M-$0.78N/AN/AN/AN/A-151.82%-49.85%N/ALatest JATT, MIST, EPIX, and IOBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MISTMilestone Pharmaceuticals-$0.19-$0.31-$0.12-$0.31N/AN/A5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPIXESSA PharmaN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPIXESSA PharmaN/A33.1233.12IOBTIO BiotechN/A5.375.37JATTJATT AcquisitionN/A0.150.15MISTMilestone Pharmaceuticals2.1815.4015.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPIXESSA Pharma75.12%IOBTIO Biotech54.76%JATTJATT Acquisition47.97%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipEPIXESSA Pharma15.50%IOBTIO Biotech2.30%JATTJATT Acquisition20.00%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableIOBTIO Biotech3065.88 million64.37 millionNot OptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableMISTMilestone Pharmaceuticals3053.46 million48.05 millionOptionableJATT, MIST, EPIX, and IOBT HeadlinesRecent News About These CompaniesMilestone Pharmaceuticals (MIST) Upgraded to Buy: Here's WhyMay 22 at 1:01 PM | zacks.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comRTW Investments LP Sells 750,000 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST)May 18, 2025 | marketbeat.comMilestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 15, 2025 | finanznachrichten.deMilestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 14, 2025 | globenewswire.comLion Point Capital LP Trims Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)May 14, 2025 | marketbeat.comMilestone Pharmaceuticals (MIST) Expected to Announce Earnings on MondayMay 7, 2025 | marketbeat.comBoxer Capital Management LLC Purchases Shares of 309,007 Milestone Pharmaceuticals Inc. (NASDAQ:MIST)May 4, 2025 | marketbeat.comNantahala Capital Management LLC Has $3.41 Million Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)April 30, 2025 | marketbeat.comMilestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVTApril 9, 2025 | seekingalpha.comMIST Stock Falls 66% Following Complete Response Letter for CardamystApril 2, 2025 | zacks.comMilestone Pharmaceuticals price target lowered to $10 from $25 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comTD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertaintyApril 2, 2025 | finance.yahoo.comMilestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD CowenApril 2, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Shares Hit New Low After FDA Rejects EtripamilMarch 29, 2025 | marketwatch.comMilestone Stock Crashes After Surprise Tachycardia Drug RejectionMarch 29, 2025 | biospace.comMilestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVTMarch 28, 2025 | finanznachrichten.deMilestone stock tumbles after FDA letter on etripamilMarch 28, 2025 | ca.investing.comManufacturing issues trip up Milestone's long-awaited FDA landmarkMarch 28, 2025 | fiercepharma.comMilestone Pharmaceuticals announces FDA issued CRL for etripamilMarch 28, 2025 | markets.businessinsider.comMilestone flagging following CRLMarch 28, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryBy Jeffrey Neal Johnson | April 27, 2025View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoverySouthwest Airlines CEO Calls Recession, Why Option Traders JumpedBy Gabriel Osorio-Mazilli | April 29, 2025View Southwest Airlines CEO Calls Recession, Why Option Traders JumpedJATT, MIST, EPIX, and IOBT Company DescriptionsESSA Pharma NASDAQ:EPIX$1.69 +0.03 (+1.81%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.30%) As of 05/23/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.IO Biotech NASDAQ:IOBT$1.21 +0.01 (+0.83%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.16 -0.05 (-4.55%) As of 05/23/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.JATT Acquisition NYSE:JATT$1.04 +0.01 (+0.97%) As of 05/22/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Milestone Pharmaceuticals NASDAQ:MIST$1.54 +0.15 (+10.79%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.53 -0.01 (-0.65%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
